A phase 2 trial of veliparib (ABT-888) and local exposure to radiation preceded by veliparib with TMZ as a maintenance therapy, in recently detected high-grade glioma patients without mutations in BRAFV600 and H3 K27M.A randomized trial of phase II/III using placebo or veliparib with TMZ (combination) in GBM patients who are newly diagnosed with hypermethylation of MGMT promoter. Here, MGMT is linked to glioma.